Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Aptevo Therapeutics Inc. APVO

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.02
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
3.44
Revenue
12.99
Net Income
(26.41)
Free Cash Flow
(25.34)
Net Debt
(9.80)
Current Ratio
2.08
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.17
P/B ratio
0.36
Past 5Y EPS Growth
80.96%
This Y EPS Growth
80.47%
Next Y EPS Growth
61.33%
Next 5Y EPS Growth
58.56%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 16.90 8.71 21.62 9.80
Receivables — — — —
Inventory — — — —
Other 0.69 0.26 — —
19.07 10.66 23.08 10.80
2023 2024 2025 Q'26
Payables 3.98 1.24 0.88 1.16
ST’ Debt — — — —
Other 1.14 1.30 — —
7.22 6.21 6.05 5.19
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’22 3.11 — — —
3.11
’21 2.42 3.11 3.10 3.67
12.29
’20 — 0.47 1.46 2.37
4.31
’19 7.02 7.36 9.01 9.03
32.42
’18 4.07 6.83 5.82 6.35
23.07
’17 2.14 3.53 6.17 2.82
14.66
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (7.96) (5.45) — —
—
’25 (6.57) (7.09) (6.69) (5.24)
(25.59)
’24 (6.65) (6.15) (5.22) (5.76)
(23.78)
’23 4.57 (4.80) (6.24) (5.25)
(11.73)
’22 (5.12) (3.07) (6.90) (5.94)
(21.02)
’21 (7.50) (5.05) (5.24) (3.88)
(21.68)
’20 (11.17) (4.63) (7.39) (6.12)
(29.32)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (7.96) (5.45) — —
—
’25 (6.57) (7.09) (6.69) (5.24)
(25.59)
’24 (6.65) (6.15) (5.22) (5.76)
(23.78)
’23 4.57 (4.80) (6.24) (5.25)
(11.73)
’22 (5.12) (3.09) (6.90) (5.94)
(21.05)
’21 (7.69) (5.44) (5.25) (4.00)
(22.39)
’20 (11.17) (4.63) (7.39) (6.21)
(29.41)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (6.41) (5.31) — —
—
’25 (1.58k) (151.08) (40.11) —
(87.27)
’24 (129.68k) (21.77k) (6.26k) —
(31.43k)
’23 223.92k (706.20k) (287.07k) —
(815.28k)
’22 (889.92k) 3.20m (861.21k) (0.72)
901.40k
’21 (941.59k) (1.00m) (821.02k) (1.28)
(3.49m)
’20 510.99k (1.21m) (1.21m) (1.72)
(5.23)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,136,995.25 89,084.16 1,314.00 9.07 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,010,984.00 1,512,086.38 143,856.00 1,976.40 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 45 40 42 36 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.07 0.00 0.00 0.00 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.11 — — — ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 100.00% — — — — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.01 (18.65) (24.13) (25.97) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 225.24% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.03 (17.41) (24.13) (25.97) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.90 0.57 0.35 0.24 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.61 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 901,404.90 (815,283.40) (31,431.65) (87.27) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.12) 0.00 (29,731.25) (81.12) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.13) 0.00 (29,731.25) (81.12) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.52 0.00 5,943.75 55.09 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.10 0.00 0.00 0.32 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.92 — — — ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 527,133.51 — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 380,818.33 — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 527,132.03 — — — ‡‡‡‡ ‡‡‡‡ —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (323,341.18) — — — — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.02) (11.73) (23.78) (25.59) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.03) — — — — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.05) (11.73) (23.78) (25.59) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.74 11.84 4.45 17.03 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.46 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.18) (16.90) (8.71) (21.62) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.97 12.22 4.76 17.38 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.68% (58.96%) (119.36%) (128.73%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.66% (115.32%) (284.28%) (248.81%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Aptevo Therapeutics (APVO), a lean clinical-stage biotech with 42 employees focused on immunotherapy for hematologic cancers like AML, has endured a brutal revenue rollercoaster since its 2018 spin-off. Peak sales of $32 million in 2019 from rituximab biosimilars gave way to an 87% plunge by 2020 amid COVID disruptions and pipeline setbacks, culminating in zero revenue in 2023-2024. While gross margins flipped to 100% on sparse high-margin deals, persistent operating cash burns—nearing $24 million in 2024—and wild swings in net income underscore the classic biotech volatility, with a now-modest net cash position offering limited runway absent milestones.

The balance sheet shows strain but some stabilization: debt slashed 86%, equity recovering slightly to $4.8 million, yet ROE and ROA remain deeply negative amid dilution from reverse splits. Analyst forecasts predict a tepid revenue rebound to $6.7 million through 2027 but deepening losses to -$29 million, betting on binary catalysts like APVO436 trial data without near-term profitability. A recent insider purchase adds intrigue, aligning with unanimous analyst targets implying over 5,500% upside—tempting for lottery-ticket plays, but execution risks and cash conundrums demand caution.

This phoenix narrative tempts amid AML’s $5 billion market, yet downside looms large: trial flops could accelerate dilution and delisting threats. Risk-averse investors should scrutinize the full analysis for whether insider conviction and pipeline momentum outweigh the biotech graveyard’s precedents.

Read full commentary →

Aptevo Therapeutics Inc. (APVO) Latest News

News by impact score

Fine-tune

3 Sep

4 investorshub.advfn.com, 10:19 AM
Aptevo Therapeutics reports 93% clinical benefit rate for mipletamig triplet in TP53-mutated AML. Strong clinical results for core drug candidate significantly enhance Aptevo's development outlook and market position.

4 , 8:05 AM
Aptevo Therapeutics reports 93% clinical benefit rate with Mipletamig triplet in TP53-mutated frontline AML. Strong efficacy data in hard-to-treat AML subset advances Mipletamig development and supports future valuation.

24 Aug

4 , 5:02 AM
Aptevo Therapeutics Inc. is concentrating efforts on three primary development areas to advance its therapeutic pipeline and market position. Strategic focus on three key development areas signals major initiatives likely to alter company trajectory and investor sentiment.

14 Aug

3 , 8:05 AM
Aptevo Therapeutics Inc. reported second quarter 2026 financial results and issued a business update. Quarterly earnings release supplies routine financial data with limited effect on long-term trajectory.

27 Jul

3 , 8:05 AM
Aptevo Therapeutics files patent for Nectin-4 x PD-L1 dual targeting backbone to strengthen solid tumor strategy. Patent filing advances dual-targeting oncology approach and may support future product positioning.

30 Jun

3 , 8:05 AM
Aptevo Therapeutics secured a $1.5 million non-dilutive research grant from the Andy Hill Care Fund to advance development of APVO451, a Nectin-4-targeted trispecific immunotherapy for solid tumors. Non-dilutive grant funds early-stage advancement of new oncology candidate APVO451.

16 Jun

4 , 5:15 AM
Aptevo Therapeutics Inc. receives new coverage initiation centered on its multispecific immune engagement platform and next-generation therapies. Coverage launch spotlighting Aptevo's multispecific immune technologies is likely to drive notable investor attention and shift market positioning.

27 May

4 ACCESS Newswire, 8:05 AM
Aptevo Therapeutics and Niowave launch a strategic collaboration to develop radiopharmaceutical therapeutics, including a strategic equity investment by Niowave at closing. Collaboration plus equity investment delivers major strategic and financial support to Aptevo's radiopharmaceutical pipeline.

20 May

3 Zacks, 12:00 PM
Aptevo Therapeutics Inc. (APVO) receives a rating upgrade to Buy. Buy rating upgrade may lift near-term investor sentiment and APVO share price.

13 May

4 ACCESS Newswire, 8:05 AM
Aptevo Therapeutics issued a 1Q26 business update confirming the RAINIER trial remains on track for 2026 completion and upcoming Phase 2 dose selection. RAINIER trial progress toward 2026 completion and Phase 2 dose selection represents a major clinical milestone boosting APVO's pipeline and investor outlook.

6 May

5 ACCESS Newswire, 8:05 AM
Aptevo Therapeutics reports 87% clinical benefit rate and 81% remission in 31 evaluable frontline AML patients through Cohort 5, substantially outperforming benchmarks. RAINIER trial remains on track for 2026 completion and Phase 2 dose selection. Exceptional AML trial results with 87% clinical benefit and 81% remission rates outperform benchmarks, advancing RAINIER to Phase 2 and positioning APVO for transformative growth.

10 Apr

3 Zacks, 12:00 PM
Analysts upgraded Aptevo Therapeutics (APVO) to Buy rating, citing promising clinical progress in its oncology pipeline, undervalued stock, and potential for upcoming milestones. Analyst upgrade to Buy highlights clinical advancements and undervaluation, likely improving investor sentiment and near-term market performance.

10 Mar

4 ACCESS Newswire, 8:05 AM
Aptevo Therapeutics Inc. (APVO) reports mipletamig achieving an 86% clinical benefit rate with no cytokine release syndrome (CRS) in acute myeloid leukemia (AML) patients, as evaluable patient data expands by nearly 50%. Mipletamig's strong 86% clinical benefit rate without CRS in expanded AML data signals major potential for APVO's pipeline advancement and investor enthusiasm.

3 Feb

4 ACCESS Newswire, 8:05 AM
Aptevo Therapeutics Inc. announced executive leadership transitions aimed at supporting its next phase of growth. The company appointed a new Chief Executive Officer and a new Chief Financial Officer, emphasizing a strategic focus on advancing its pipeline and enhancing operational efficiency. These changes are intended to position Aptevo for future success and align with its growth objectives in the biotechnology sector. Leadership transitions at the executive level can significantly impact strategic direction and operational effectiveness, influencing future growth and market performance.

9 Jan

4 ACCESS Newswire, 8:05 AM
Aptevo Therapeutics Inc. has secured a $60 million equity line of credit aimed at advancing its multispecific portfolio and enhancing strategic options. This funding will support the company's ongoing development efforts and potentially accelerate its growth initiatives in the biotechnology sector. The equity line of credit is a significant financial move that could enhance product development and strategic flexibility.

26 Dec

3 ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresInvestopediaMT NewswiresMT NewswiresMT Newswires, 8:05 AM
Aptevo Therapeutics Inc. announced a 1-for-18 reverse stock split, effective on October 30, 2023. This move aims to increase the per-share trading price of its common stock to meet the minimum bid price requirement for continued listing on the Nasdaq. The reverse split will reduce the number of outstanding shares, but the overall value of shareholders' investments will remain unchanged. Aptevo's management believes this action is necessary to enhance the company's market position and attract institutional investors. The reverse stock split is a strategic move to maintain Nasdaq listing, which may influence investor sentiment and market perception.

9 Dec

4 ACCESS Newswire, 8:05 AM
Aptevo Therapeutics Inc. presented promising data on Mipletamig for frontline Acute Myeloid Leukemia (AML) at the ASH 2025 conference, highlighting its strong safety profile and high remission rates. The findings suggest that Mipletamig could be a significant advancement in AML treatment, potentially improving patient outcomes and positioning Aptevo favorably in the oncology market. Strong remission rates and safety data for Mipletamig could significantly enhance Aptevo's market position and investor sentiment.

19 Nov

3 Zacks, 9:55 AM
Aptevo Therapeutics Inc. (APVO) is showing signs of potential recovery, with analysts suggesting that the stock may soon reach a bottom. Factors contributing to this outlook include recent developments in the company's pipeline and market conditions that could favor a rebound. Investors are encouraged to consider buying the stock now, as it may present a favorable entry point before a possible upswing. Recent developments in the company's pipeline could moderately influence its financial performance and market sentiment.

10 Nov

4 ACCESS NewswireMT NewswiresClinical Trials ArenaMedical Device NetworkClinical Trials Arena, 8:05 AM
Aptevo Therapeutics Inc. has introduced its first trispecific antibody candidate, APVO451, which has shown promising preclinical data indicating immune activation in challenging solid tumors. This development marks a significant advancement in Aptevo's therapeutic pipeline, potentially addressing unmet medical needs in oncology. The introduction of APVO451 represents a major strategic move that could significantly alter the company's trajectory and investor sentiment.

6 Nov

3 , 8:05 AM
Aptevo Therapeutics Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and providing a business update. The company discussed its ongoing projects, financial performance, and strategic initiatives aimed at enhancing its market position. Management emphasized their commitment to innovation and growth in the therapeutic landscape, outlining future plans and expectations. The financial results and business update indicate moderate influence on Aptevo's financial performance and strategic direction.

8 Oct

3 ACCESS Newswire, 8:20 AM
Aptevo Therapeutics Inc. (APVO) is set to present scientific and clinical updates at the upcoming SITC and ASH conferences. Additionally, the company will participate in several leading financial and industry conferences during the fourth quarter, highlighting its ongoing commitment to advancing its research and development efforts. Participation in major conferences may enhance visibility and networking opportunities, potentially impacting product innovation and market positioning.

16 Sep

4 , 8:30 AM
Aptevo Therapeutics Inc. announced that Mipletamig achieved a 100% remission rate in Cohort 3 of the RAINIER Trial for acute myeloid leukemia (AML). This promising result highlights the potential of Mipletamig as a treatment option for AML patients, showcasing its efficacy in a clinical setting. The trial's success may pave the way for further development and regulatory approval, enhancing Aptevo's position in the oncology market. The 100% remission rate in a clinical trial for AML represents a significant advancement in treatment options, likely impacting Aptevo's market position and investor sentiment.

4 Sep

4 ACCESS Newswire, 8:45 AM
Aptevo Therapeutics Inc. has introduced two next-generation trispecific antibodies, expanding its CD3 oncology pipeline to five molecules. These innovative therapies are designed to enhance the treatment of cancer by targeting multiple antigens simultaneously, potentially improving efficacy and safety profiles. The company aims to leverage these advancements to strengthen its position in the competitive oncology market. The introduction of two next-generation trispecifics represents a significant strategic move that could enhance Aptevo's competitive positioning and market presence in oncology.

13 Aug

4 , 8:05 AM
Aptevo Therapeutics Inc. has highlighted APVO442, a preclinical candidate targeting CD3 for the treatment of prostate cancer. The candidate is designed to engage T cells to attack prostate cancer cells, showcasing potential for significant therapeutic benefits. Aptevo is advancing its development and plans to present further data at upcoming scientific conferences, emphasizing its commitment to addressing unmet medical needs in oncology. The development of APVO442 represents a significant strategic move that could enhance Aptevo's position in the oncology market.

11 Aug

3 , 8:05 AM
Aptevo Therapeutics Inc. reported its financial results for the second quarter of 2025, highlighting key metrics and providing updates on its business operations. The company discussed its ongoing projects, financial performance, and strategic initiatives aimed at enhancing growth and innovation in its therapeutic offerings. Management expressed optimism about future prospects and outlined plans for upcoming product developments. The financial results and business updates indicate moderate influence on Aptevo's performance and market positioning.

15 Jul

4 Insider Monkey, 4:57 PM
Aptevo Therapeutics Inc. (NASDAQ:APVO) has regained compliance with Nasdaq's $2.5 million stockholders’ equity requirement after raising approximately $15.9 million in gross proceeds. The company believes it has achieved the necessary equity mark and recently added preclinical candidate APVO455 to its offerings, targeting hematologic and solid tumors. Founded in 2016, Aptevo focuses on immunotherapeutic solutions for cancer using its ADAPTIR platforms. Regaining compliance with Nasdaq's equity requirement and the introduction of a new preclinical candidate are significant strategic moves that could positively influence the company's future performance.

21 Jun

4 TipRanks, 9:00 AM
Aptevo Therapeutics (APVO) has added preclinical candidate APVO455 to its portfolio of CD3-directed candidates, which utilize the CRIS-7 derived CD3 binding domain. This addition brings the total to three CD3-engaging molecules, all designed to activate tumor-specific immune responses while minimizing systemic toxicity. The suite includes Mipletamig, currently in Phase 1b/2 for frontline AML, and APVO442, a PSMA x CD3 candidate targeting prostate cancer in preclinical development. APVO455 targets multiple solid tumor types. The introduction of APVO455 and the expansion of the CD3-directed portfolio are significant strategic moves that could enhance Aptevo's competitive positioning and market potential.

18 Jun

4 ACCESS Newswire, 8:01 AM
Aptevo Therapeutics announced promising results from its Phase 1b/2 RAINIER trial of mipletamig, a bispecific antibody for acute myeloid leukemia (AML), showing an 85% remission rate in evaluable frontline patients. The combination therapy with venetoclax and azacitidine demonstrated a strong safety profile, with no dose-limiting toxicities or cytokine release syndrome reported. Mipletamig's unique CD3 engineering strategy aims to enhance anti-cancer activity while minimizing toxicity. The trial is nearing full enrollment for its highest dose level, reinforcing mipletamig's potential to reshape frontline AML treatment for unfit patients and advance standard care. The significant remission rate and strong safety profile of mipletamig could notably enhance Aptevo's market position and investor sentiment.

3 , 10:52 AM
Aptevo Therapeutics Inc. has announced an $8 million offering priced at-the-market under Nasdaq rules. The offering is expected to enhance the company's financial position and support its ongoing operations and development initiatives. The offering may provide necessary funding for operations and development, but its overall impact on the company's trajectory is expected to be limited.

13 Jun

3 , 8:05 AM
Aptevo Therapeutics Inc. is participating in the BIO International Convention, showcasing its innovative therapies and engaging with industry leaders. The event provides a platform for networking and collaboration, highlighting Aptevo's commitment to advancing biotechnology and its product pipeline. Participation in a major industry convention can enhance visibility and networking opportunities, potentially influencing future collaborations and market sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us